<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study concerns 20 patients with cerebrovascular disease in the course of oral contraception with <z:chebi fb="1" ids="50114">estrogens</z:chebi>/<z:chebi fb="0" ids="50745">progestins</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The assumption of oral contraceptives appears to be related to the cerebrovascular manifestations, which could be caused by alterations of the blood vessel walls or of the coagulative process induced by <z:chebi fb="1" ids="50114">estrogens</z:chebi>/<z:chebi fb="0" ids="50745">progestins</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>The thrombogenic action of these substances could be enhanced by preexisting conditions such as protein C or <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e> </plain></SENT>
</text></document>